Samsung Biologics Co.,Ltd. (207940.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	4546.8B	4557.0B	3497.1B	3694.6B	3001.3B
Cost of Revenue	2021.6B	2072.4B	1815.6B	1923.8B	1559.6B
Gross Profit	2525.2B	2484.6B	1681.6B	1770.8B	1441.7B
Operating Expenses
R&D Expense	145.0B	37.2B	36.7B	81.6B	160.4B
SG&A Expense	261.5B	372.2B	318.8B	565.2B	290.3B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	131.5B	6.0B	4.7B	10.3B	7.4B
Total Operating Expenses	538.1B	415.4B	360.2B	657.1B	458.1B
Cost and Expenses	2559.8B	2487.8B	2175.8B	2580.9B	2017.7B
Operating Income (EBIT)	1987.1B	2069.2B	1321.4B	1113.7B	983.6B
Non-Operating
Interest Income	47.7B	46.0B	63.8B	95.7B	53.3B
Interest Expense	26.9B	29.2B	50.1B	81.6B	64.1B
Net Interest Income	20.8B	16.9B	13.8B	14.1B	(10.8B)
Other Non-Op Income/Expense	448.5B	49.4B	63.5B	6.3B	25.4B
Non-Operating Income (excl Interest)	(468.4B)	(78.6B)	(113.6B)	(87.9B)	(89.5B)
EBT (Pre-Tax Income)	2435.5B	2118.6B	1384.9B	1120.0B	1009.0B
Income Tax Expense	621.2B	504.3B	344.6B	262.3B	211.0B
Bottom Line
Net Income	1984.4B	1784.4B	1083.3B	857.7B	798.1B
Earnings from Cont. Ops	1814.3B	1614.3B	1040.3B	857.7B	798.1B
Earnings from Discont. Ops	170.0B	170.0B	43.0B	—	—
Bottom Line Net Income	1984.4B	1784.4B	1083.3B	857.7B	798.1B
Per Share
Basic EPS	₩42,889	₩38,588	₩23,402	₩18,528	₩17,592
Diluted EPS	₩42,889	₩38,588	₩23,402	₩18,528	₩17,576
Revenue Per Share	₩98,222	₩98,550	₩75,547	₩79,812	₩66,162
Shares
Basic Shares Outstanding	46.3M	46.2M	46.3M	46.3M	45.4M
Diluted Shares Outstanding	46.3M	46.2M	46.3M	46.3M	45.4M
Profitability Metrics
EBITDA	2954.2B	2781.4B	2034.0B	1691.4B	1381.4B
D&A	498.7B	633.6B	599.1B	489.8B	308.3B
EBIT	2455.5B	2147.8B	1434.9B	1201.6B	1073.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026